What is KYTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.40B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KYTX?

P/E (TTM) is n/a and 52-week range is $5.96 to $13.67 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KYTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KYTX?

The company profile lists net income (TTM) near $-178M, EPS (TTM) near $-2.94 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Kyverna Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Emeryville, California, US, 60.8M shares outstanding, ISIN US5019761049 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Kyverna Therapeutics Inc

$KYTX

Health Care · Biotechnology

IR Run Scenarios

$6.39

+3.40%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 134 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Employees

134

Website

kyvernatx.com/

IPO

2024-02-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)